Company Overview of X-Chem, Inc.
X-Chem, Inc. operates as a subsidiary of Pharmaceutical Product Development Inc.
100 Beaver Street Suite 101
Waltham, MA 02453
Key Executives for X-Chem, Inc.
X-Chem, Inc. does not have any Key Executives recorded.
X-Chem, Inc. Key Developments
X-Chem Licenses Cardiovascular Drug Discovery Program to Bayer Pharma AG
Dec 17 14
X-Chem, Inc. announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012. The latest program comprises several series of small molecule compounds against a cardiovascular drug target. Under the terms of this agreement, X-Chem will receive an upfront license fee in addition to payments based on the achievement of defined pre-clinical, clinical and sales milestones, as well as royalties. This license further validates the innovative nature of X-Chem’s team and approach.
X-Chem Signs Drug Discovery Collaboration with Alexion
Dec 15 14
X-Chem has signed drug discovery collaboration with Alexion. The contract has been signed for new therapies to treat patients with severe and ultra-rare disorders. According to the agreement, X-Chem will deploy its drug discovery engine, which is based on an ultra-large, high-diversity library in excess of 100 billion molecules, to identify new drug candidates against targets chosen by Alexion. The contract will see X-Chem receive an upfront payment and receive additional payments upon the achievement of specified research, development and regulatory milestones. X-Chem will also receive royalty payments on the sale of products resulting from the collaboration.
X-Chem Enters into Multi-Target Collaboration with Pfizer Inc
Jun 11 14
X-Chem, Inc. announced a multi-target collaboration with Pfizer Inc. The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases. Under the terms of the agreement, X-Chem is applying its discovery engine, which leverages a high diversity, proprietary DNA-encoded small molecule library to seek the identification of novel leads for the Pfizer programs. Pfizer has an exclusive option to license any compounds generated in the course of the collaboration. The financial terms of the agreement were not disclosed.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 25, 2014
Most Searched Private Companies
Sponsored Financial Commentaries